- The IMS Institute for Healthcare Informatics states that “the strategies that pharmaceutical companies use to engage with social media could be categorized as low-risk and less innovative than those employed in other industries.”
- The pharmaceutical industry has been slow to embrace social media.
- One reason is the lack of guidance from health regulators about using social media. In the US, for example.
- Users of social media now expect to be able to have a conversation with pharmaceutical companies when they face uncertainties.
KEY TAKEAWAY: Patients and caregivers want to better understand chronic health conditions and, more importantly, what to expect when evaluating different treatment options. With the increase in “fake news” pharma companies have an opportunity to really engage their audience if they can think beyond “what’s the ROI?”.